Rhythm Pharmaceuticals and LG Chem Life Sciences enter license agreement
January 5, 2024Medical Communications LG Chem Life Sciences, License Agreement, Pharmacy, Rhythm Pharmaceuticals, clinical trial
Rhythm Pharmaceuticals and LG Chem Life Sciences have announced that they have entered into a global licensing agreement for LB54640, …
Renovos Biologics gains FDA Breakthrough Device Designation for Renovite
January 4, 2024Medical Communications FDA, Musculo-skeletal disorder, Renovos Biologics, breakthrough device designation
Renovos Biologics has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its lead …
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
January 4, 2024Research and Development BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the …
C4X receives $11m milestone payment from AstraZeneca
January 3, 2024Sales and Marketing AstraZeneca, C4X, C4X Discovery, Chronic Diseases
C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca which has been triggered …
Proteome Sciences completes new facility in San Diego, US
January 3, 2024Manufacturing and Production Pharmacy, Proteome Sciences, facility, san diego
Proteome Sciences has announced that it has completed the installation and set up of equipment in its new laboratory facility …
AstraZeneca and Sanofi’s Beyfortus approved in China
January 2, 2024Research and Development AstraZeneca, Beyfortus, China, Immunology, Sanofi
AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus …
Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager
January 2, 2024Research and Development Astellas, Cancer, Elpiscience, Oncology, bispecific macrophage
Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration and license agreement for novel …
Calliditas Therapeutics gains FDA approval of Tarpeyo
December 22, 2023Medical Communications Calliditas, FDA, Nephrology, kidneys
Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to …
FDA approves AstraZeneca and Ionis’s Wainua
December 22, 2023Medical Communications AstraZeneca, FDA, Ionis, Neurology, Wainua
AstraZeneca and Ionis have announced that the US Food and Drug Administration (FDA) has approved Wainua (eplontersen) for the treatment …
Ocelot Bio gains FDA ODD for OCE-205 for ascites treatment
December 21, 2023Research and Development Gastrointestinal tract, Ocelot Bio, ascites
Ocelot Bio has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to OCE-205 …
Tracon Pharmaceuticals shares update on ENVASARC phase 2 trial
December 21, 2023Research and Development ENVASARC, Pharmacy, Tracon Pharmaceuticals, clinical trial
Tracon Pharmaceuticals has shared an update from the ongoing phase 2 ENVASARC trial, which has now enrolled more than 70 …
Gilead and Compugen enter exclusive license agreement for immunotherapy programme
December 20, 2023Research and Development Gilead Sciences, Immunology, License Agreement, compugen, immunology
Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, …
Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics
December 20, 2023Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin
Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …
BioNTech achieves milestone at vaccine manufacturing site in Rwanda
December 19, 2023Manufacturing and Production BioNTech, Immunology, manufacturing, rwanda
BioNTech has announced that it has reached the next milestone in the establishment of its mRNA vaccine manufacturing capacities in …
Elekta and BMS partner for digital treatment for melanoma
December 19, 2023Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …
GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment
December 18, 2023Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer
GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …
InnoCare shares results from phase 2 trial for atopic dermatitis treatment
December 18, 2023Research and Development Dermatology, InnoCare, atopic dermatitis, clinical trial
InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met …
FDA approves Glaukos’ iDose TR treatment for glaucoma disease
December 15, 2023Medical Communications FDA, Glaukos, Opthalmology, iDose TR, ocular hypertension, open-angle glaucoma
Glaukos Corporation has announced that the US Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for …
First patient dosed in Cullinan Oncology’s phase 1 trial for CLN-617
December 15, 2023Research and Development Cullinan Oncology, Oncology, clinical trial, tumours
Cullinan Oncology has announced that the first patient has been dosed with CLN-617 in its phase 1 clinical trial, designed …
FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment
December 14, 2023Medical Communications FDA, Mission Therapeutics, Nephrology, acute kidney injury, clinical trial
Mission Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application …
Latest content
FibroFind appoints Lee Borthwick as CEO
